Formulation Process And Analytical Development Capabilities

By Elizabeth Miller, Samaresh Sau Ph.D., Bhuvaneshwar Vaidya, Ph.D., Mahesh Karwa Ph.D., Millipore Sigma, Indianapolis, USA, and Gaëlle Béalle, Ph.D., Merck Millipore SAS, Molsheim, France

GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy

Explore process and analytical development capabilities that can help you advance your formulation to GMP Manufacturing. Leveraging cutting-edge technology and expertise in various lipid-based formulations for diverse payloads and therapeutic applications, MilliporeSigma develops, optimizes, and scales up your process. Continue reading to learn more about this CTDMO offering.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development